Type 2 Diabetes Algorithm Treats to HbA_1c Goals

▸ The algorithm should conform as nearly as possible to consensus of expert endocrinologists who manage patients with type 2 diabetes, and should provide specific guidance to physicians with prioritization and rationale for the selection of any particular regimen.

Dr. Rodbard has received consultant honoraria from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biodel Inc., GlaxoSmithKline, MannKind Corp., Merck & Co., Novo Nordisk Inc., Sanofi-Aventis U.S., and Takeda Pharmaceuticals America Inc. She also receives speaker honoraria and/or research grant support from some of those companies, as well as from Amylin Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, and MacroGenics Inc.

Dr. Jellinger has received speaker honoraria from Amylin, Lilly, Merck, Novo-Nordisk, Sanofi-Aventis, and Takeda, and consultant honoraria from Daiichi Sankyo Inc., MannKind, and Tethys Bioscience.

Dr. Nathan has received a research grant for investigator-initiated research support from Sanofi-Aventis and support for educational programs from GlaxoSmithKline.

'We need to consider the total cost of care, which is overwhelmingly driven by the cost of complications.'

Source DR. RODBARD